Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Investor Reminder (KYTX): Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of February 7, 2025 Deadline

By: TheNewswire.com
<div><p>RADNOR, PA - (<a href="https://www.newmediawire.com">NewMediaWire</a>) - December 24, 2024 - The law firm of <a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">Kessler Topaz Meltzer &amp; Check, LLP</a> (<a href="http://www.ktmc.com">www.ktmc.com</a>) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (&ldquo;Kyverna&rdquo;) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna&rsquo;s February 8, 2024 initial public offering (&rdquo;IPO&rdquo;). <strong>The lead plaintiff deadline is February 7, 2025.</strong></p> <figure align="left" style="width: 240px; max-width: 100%; margin-bottom: 20px; float: left; margin-right: 20px;"><img src="http://newmediawire.s3.amazonaws.com/6769cf68da846f3dd21a4a7d_1" alt="" width="240" style="width: 240px; max-width: 100%; height: auto;" /></figure> <p><strong><u>CONTACT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: <br /></u></strong><strong>If you suffered Kyverna losses, you may</strong> <a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r"><strong>CLICK HERE</strong></a><strong> or copy and paste this link into your browser: </strong><a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r</a></p> <p><strong>You can also contact attorney </strong><a href="mailto:Jonathan%20Naji,%20Esq."><strong>Jonathan Naji, Esq.</strong></a><strong> by calling (484) 270-1453 or by email at </strong><a href="mailto:info@ktmc.com"><strong>info@ktmc.com</strong></a><strong>. </strong></p> <p><strong><u>DEFENDANTS&rsquo; ALLEGED MISCONDUCT:</u><br /></strong>The complaint alleges that, in the prospectus and registration statements issued in connection with the IPO, Defendants made materially false and/or misleading statements and/or omissions regarding the company&rsquo;s business, operations, and prospects.&nbsp; Specifically, Defendants made false and/or misleading statements regarding, and/or failed to disclose, that Kyverna possessed adverse data related to one of its clinical trials at the time of its IPO.</p> <p><strong><u>THE LEAD PLAINTIFF PROCESS:</u><br /></strong>Kyverna<strong><em> </em></strong>investors may, <u><strong><em>no later than February 7, 2025,</em></strong></u> seek to be appointed as a lead plaintiff representative of the class through <a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">Kessler Topaz Meltzer &amp; Check, LLP</a> or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.&nbsp; The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.</p> <p><a href="https://www.ktmc.com">Kessler Topaz Meltzer &amp; Check, LLP</a> encourages Kyverna investors who have suffered significant losses to contact the firm directly to acquire more information.</p> <p><a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r"><strong>CLICK HERE</strong></a><strong> TO SIGN UP FOR THE CASE OR COPY AND PASTE THIS LINK INTO YOUR BROWSER: </strong><a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r</a></p> <p><strong><u>ABOUT KESSLER TOPAZ MELTZER &amp; CHECK, LLP:&nbsp;</u> &nbsp; &nbsp;</strong></p> <p><a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">Kessler Topaz Meltzer &amp; Check, LLP</a> prosecutes class actions in state and federal courts throughout the country and around the world.&nbsp; The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer &amp; Check, LLP. For more information about <a href="https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=kytx&amp;mktm=r">Kessler Topaz Meltzer &amp; Check, LLP</a> please visit <a href="http://www.ktmc.com">www.ktmc.com</a>.</p> <p><strong>CONTACT:<br /></strong>Kessler Topaz Meltzer &amp; Check, LLP<br />Jonathan Naji, Esq.<br />(484) 270-1453<br />280 King of Prussia Road<br />Radnor, PA 19087<br /><a href="mailto:info@ktmc.com">info@ktmc.com</a></p> <p>May be considered attorney advertising in certain jurisdictions.&nbsp; Past results do not guarantee future outcomes.</p><p class="nmw_link">View the original release on <a href="https://www.newmediawire.com/nmw_release/?rid=6769cf68da846f3dd21a4a7d/investor-reminder-kytx-kessler-topaz-meltzer-check-llp-reminds-kyverna-therapeutics-inc-kytx-investors-of-february-7-2025-deadline">www.newmediawire.com</a></p></div>
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.